Treats relapsing forms of multiple sclerosis (MS). ANDA 209623, held by Msn. Teriflunomide.
As of Nov 16, 2026, ANDA 209623 (Teriflunomide), held by Msn, was first approved by FDA on Apr 24, 2019, with 5 approved supplements and 0 published complete response letters.
Teriflunomide tablet is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 24, 2019 | Original application | Approved | None posted |
| Teriflunomide7MG · tablet;oral | Teriflunomide | Rx |
| Teriflunomide14MG · tablet;oral | Teriflunomide | Rx |
| Aug 6, 2025 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 1, 2022 | Supplement 4Labeling · Standard review | Approved | None posted |
| Apr 23, 2021 | Supplement 3Labeling · Standard review | Approved | None posted |
| Dec 15, 2020 | Supplement 1Labeling · Standard review | Approved | None posted |
| Dec 15, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 24, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters